Temporal trend and potential impact of angiotensin receptorneprilysin inhibitors on transcatheter edge-to-edge mitral valve repair

Autor: Barrero A, Carrasco-Chinchilla F, Benito-González T, Pascual I, Arzamendi D, Estévez-Loureiro R, Nombela-Franco L, Pan M, Freixa X, Trillo-Nouche R, Sánchez-Recalde Á, Andraka L, Cruz-González I, López-Mínguez JR, Diez Gil JL, Urbano-Carrillo C, Sanmiguel Cervera D, Sanchis J, Bosa F, Ruiz V, Del Trigo M, Molina E, Serrador AM, Alonso-Briales JH, Garrote C, Avanzas P, Li CH, Baz JA, Jiménez-Quevedo P, Mesa D, Regueiro A, Cid B, Carrasco-Moraleja M, Rodríguez-Gabella T, Hernández-García JM, Fernández-Vázquez F, Amat-Santos IJ, Spanish TEER Group
Rok vydání: 2022
Předmět:
Zdroj: Revista Espanola De Cardiologia (english Ed.)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Revista espanola de cardiologia (English ed.)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
ISSN: 1885-5857
Popis: INTRODUCTION AND OBJECTIVES: Transcatheter edge-to-edge repair (TEER) should be considered in patients with heart failure and secondary mitral regurgitation (MR). Angiotensin receptor-neprilysin inhibitors (ARNIs) have been demonstrated to improve prognosis in heart failure. We aimed to evaluate the impact ARNIs on patient selection and outcomes.; METHODS: The population of the Spanish TEER prospective registry (March 2012 to January 2021) was divided into 2 groups: a) TEER before the ARNI era (n=450) and b) TEER after the recommendation of ARNIs by European Guidelines (n=639), with further analysis according to intake (n=52) or not (n=587) of ARNIs.; RESULTS: A total of 1089 consecutive patients underwent TEER for secondary MR. In the ARNI era, there was a reduction in left ventricle dilation (82mL vs 100mL, P=.025), and better function (35% vs 38%, P=.011). At 2 years of follow-up, mortality (10.6% vs 17.3%, P
Databáze: OpenAIRE
Externí odkaz: